Kazia Therapeutics Limited ADR (NASDAQ:KZIA) has a beta value of 2.22 and has seen 0.18 million shares traded in the last trading session. The company, currently valued at $2.96M, closed the last trade at $0.89 per share which meant it lost -$0.05 on the day or -5.29% during that session. The KZIA stock price is -1675.28% off its 52-week high price of $15.80 and -1.12% below the 52-week low of $0.90. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.35 million shares traded. The 3-month trading volume is 1.87 million shares.
The consensus among analysts is that Kazia Therapeutics Limited ADR (KZIA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
Kazia Therapeutics Limited ADR (NASDAQ:KZIA) trade information
Sporting -5.29% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the KZIA stock price touched $0.89 or saw a rise of 35.04%. Year-to-date, Kazia Therapeutics Limited ADR shares have moved -49.72%, while the 5-day performance has seen it change -29.37%. Over the past 30 days, the shares of Kazia Therapeutics Limited ADR (NASDAQ:KZIA) have changed -42.58%. Short interest in the company has seen 0.92 million shares shorted with days to cover at 0.18.
Kazia Therapeutics Limited ADR (KZIA) estimates and forecasts
The company’s shares have lost -75.10% over the past 6 months. If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 11.47% over the past 5 years.
KZIA Dividends
Kazia Therapeutics Limited ADR is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Kazia Therapeutics Limited ADR (NASDAQ:KZIA)’s Major holders
Investors are also buoyed by the number of investors in a company, with Kazia Therapeutics Limited ADR having a total of 15.0 institutions that hold shares in the company. The top two institutional holders are MORGAN STANLEY with over 0.2 million shares worth more than $45967.0. As of 2024-06-30, MORGAN STANLEY held 0.8386% of shares outstanding.
The other major institutional holder is BNP PARIBAS ARBITRAGE, SNC, with the holding of over 63568.0 shares as of 2024-06-30. The firm’s total holdings are worth over $14532.0 and represent 0.2651% of shares outstanding.
